Home        About us        Research        Gallery        Funding        Education        News/Events        Publications        Links




PhD theses

Movies

Publications

Research output Angiogenesis Laboratory Amsterdam

 


     2017

Wentink MQ, Huijbers EJ, Timmerman P, Griffioen AW. Anti-tumor immune regulation by angiostatic therapy. Proc.Natl.Acad.Sci USA, In press, 2017.

Sabrkhany S, Kuijpers MJE, van Kuijk SMJ, Sanders L, Pineda S, Olde Damink SWM, Dingemans AC, Griffioen AW, Oude Egbrink MGA. A combination of platelet features allows detection of early-stage cancer. Eur J Cancer.80:5-13. doi: 10.1016/j.ejca.2017.04.010, 2017.

Zuurbier L, Rahman A, Cordes M, Scheick J, Wong TJ, Rustenburg F, Joseph JC, Dynoodt P, Casey R, Drillenburg P, Gerhards M, Barat A, Klinger R, Fender B, O'Connor DP, Betge J, Ebert MP, Gaiser T, Prehn JHM, Griffioen AW, van Grieken NCT, Ylstra B, Byrne AT, van der Flier LG, Gallagher WM, Postel R. Apelin: A putative novel predictive biomarker for bevacizumab response in colorectal cancer. Oncotarget, doi: 10.18632/oncotarget.17306, 2017.

Nowak-Sliwinska P, Griffioen AW. Angiogenesis inhibitors in combinatorial approaches. Angiogenesis, In press. 2017.

Berndsen B, Abdul UK, Weiss A, Zoetemelk M, Te Winkel MT, Dyson PJ, Griffioen AW, Nowak-Sliwinska P. Epigenetic approach for angiostatic therapy; promising combinations for cancer treatment. Angiogenesis, In press. 2017.

Van Beijnum JR, Giovannetti E, Poel D, Nowak-Sliwinska P, Griffioen AW (2017) miRNAs: microManagers of anti-cancer combination therapies. Angiogenesis, In press. 2017.

Ramjiawan RR, Griffioen AW, Duda DG (2017) Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy? Angiogenesis, In press. 2017.

Hamming LC, Slotman BJ, Verheul HMV, Thijssen VJ (2017) The clinical application of angiostatic therapy in combination with radiotherapy: past, present, future. Angiogenesis, In press. 2017.

Berndsen RH, Weiss A, Abdul UK, Wong TJ, Meraldi P, Griffioen AW, Dyson PJ, Nowak-Sliwinska P. Combination of ruthenium(II)-arene complex [Ru(η6-p-cymene)Cl2(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient angiostatic and antitumor activity. Sci Rep. 7:43005. doi: 10.1038/srep43005. 2017.

Rovithi M, Avan A, Funel N, Leon LG, Gomez VE, Wurdinger T, Griffioen AW, Verheul HM, Giovannetti E. Development of bioluminscent chick chorioallantoic membrane (CAM) models for primary pancreatic cancer cells: a platform for drug testing. Sci. Rep. 7:44686, DOI 10.1038/srep44686, 2017.

Huijbers EJ, Griffioen AW. The revival of cancer vaccines - The eminent need to activate humoral immunity.Hum Vaccin Immunother. 24:1-3. doi: 10.1080/21645515.2016.1276140. 2017.

Maracle CX, Kucharzewska P, Helder B, van der Horst C, Correa de Sampaio P, Noort AR, van Zoest K, Griffioen AW, Olsson H, Tas SW. Targeting non-canonical nuclear factor-κB signalling attenuates neovascularization in a novel 3D model of rheumatoid arthritis synovial angiogenesis. Rheumatology 56:294-302. doi: 10.1093/rheumatology/kew393. 2017


    2016

 

van Beijnum JR, Pieters W, Nowak-Sliwinska P, Griffioen AW. Insulin-like growth factor axis targeting in cancer and tumour angiogenesis - the missing link. Biol Rev Camb Philos Soc doi: 10.1111/brv.12306. 2016.

Nowak-Sliwinska P, Weiss A, Păunescu E, Clavel CM, Griffioen AW, Dyson PJ, Anti-angiogenic Properties of Chlorambucil Derivatives with Flourous and Hydrocarbon Appendages, MedChemComm, 7, 1596 - 1603, 2016

Nowak-Sliwinska P and Griffioen AW, Therapeutic potential of angiogenesis inhibitor mixtures in cancer treatment, Research and Clinical Medicine, in press, 2016.

Veluchamy JP, Spanholtz J, Tordoir M, Thijssen VL, Heideman DA, Verheul HM, de Gruijl TD, van der Vliet HJ. Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer. PLoS One. 2016 Jun 17;11(6):e0157830

Kleibeuker EA, Fokas E, Allen PD, Kersemans V, Griffioen AW, Beech J, Im JH, Smart SC, Castricum KC, van den Berg J, Schulkens IA, Hill SA, Harris AL, Slotman BJ, Verheul HM, Muschel RJ, Thijssen VL. Low dose angiostatic treatment counteracts radiotherapy-induced tumor perfusion and enhances the anti-tumor effect. Oncotarget 7:76613-27, 2016.

Wentink MQ, Hackeng TM, Tabruyn SP, Puijk WC, Schwamborn K, Altschuh D, Meloen RH, Schuurman T, Griffioen AW, Timmerman P Targeted vaccination against the bevacizumab binding site on VEGF using 3D-structured peptides elicits efficient antitumor activity. Proc.Natl.Acad.Sci USA 113:12532-7, 2016.

Rovithi M, de Haas RR, Honeywell RJ, Poel D, Peters GJ, Griffioen AW, Verheul HM. Alternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growth. J Exp Clin Cancer Res. 35:138,  2016. 

Wentink MQ, Broxterman HJ, Lam SW, Boven E, Walraven M, Griffioen AW, Pili R, van der Vliet HJ, de Gruijl TD, Verheul HM. A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer. Br J Cancer. 115:940-8, 2016.

Sabrkhany S, Griffioen AW, Pineda S, Sanders L, Mattheij N, van Geffen JP, Aarts MJ, Heemskerk JW, Oude Egbrink MG, Kuijpers MJ. Sunitinib uptake inhibits platelet function in cancer patients. Eur J Cancer 66:47-54, 2016.

Nowak-Sliwinska P, Weiss A, Ding X, Dyson PJ, Van den Bergh H, Griffioen AW, Ho CM. Optimization of drug combinations using Feedback System Control. Nature Prot. 11:302-15, 2016.

 Buikhuisen WA, Scharpfenecker M, Griffioen AW, Korse CM, van Tinteren H, Baas P. A Randomized Phase II Study Adding Axitinib to Pemetrexed-Cisplatin in Patients with Malignant Pleural Mesothelioma: A Single-Center Trial Combining Clinical and Translational Outcomes. J Thorac Oncol. 11:758-68, 2016.

van Beijnum JR, Thijssen VL, Läppchen T, Wong TJ, Verel I, Engbersen M, Schulkens IA, Rossin R, Grüll H, Griffioen AW, Nowak-Sliwinska P. A key role for galectin-1 in sprouting angiogenesis revealed by novel rationally designed antibodies. Int J Cancer. 139:824-35, 2016.

Huijbers EJ, van Beijnum JR, Thijssen VL, Sabrkhany S, Nowak-Sliwinska P, Griffioen AW. Role of the tumor stroma in resistance to anti-angiogenic therapy. Drug Resist Updat. 25:26-37, 2016.


     2015

Van Mourik TR, Läppchen T, Rossin R, Van Beijnum JR, Macdonald JR, Mayo KH, Griffioen AW, Nicolay K, Grüll H. Evaluation of 111In-labeled Anginex as Potential SPECT Tracer for Imaging of Tumor Angiogenesis. Anticancer Res. 35:5945-54, 2015.

Păunescu E, Nowak-Sliwinska P, Clavel CM, Scopelliti R, Griffioen AW, Dyson PJ. Anticancer Organometallic Osmium(II)-p-cymene Complexes. Chem Med Chem 10:1539-47, 2015.

Păunescu E, Clavel CM, Nowak-Sliwinska P, Griffioen AW, Dyson PJ. Improved angiostatic activity of dasatinib by modulation with hydrophobic chains. ACS Med Chem Lett. 6:313-7, 2015.

Sabrkhany, S, Kuijpers MJE, Verheul HMW, Griffioen AW, Oude Egbrink MGA. Platelets: an unexploited source of information in blood biomarker research. Lancet Heamatol. 2(12):e512-3. doi: 10.1016/S2352-3026(15)00225-2.. 2015.

Weiss A, Berndsen RH, Ding X, Ho CM, Dyson PJ, Van den Bergh H, Griffioen AW, Nowak-Sliwinska P. A streamlined search technology for identification of synergistic drug combinations. Sci Rep. 5:14508. doi: 10.1038/srep14508 2015.

Kleibeuker EA, Ten Hooven M, Verheul HM, Slotman BJ, Thijssen VL. Combining radiotherapy with sunitinib; Lessons (to be) learned. Angiogenesis.  In press, 2015.

Nowak-Sliwinska P, Clavel CM, Paunescu E, Te Winkel MT, Griffioen AW, Dyson PJ. Anti-aingiogenic and anticancer properties of bifunctional ruthenium(II)-p-cymene complexes: the influence of pendant perfluorous chains. Mol Pharm. 12:3089-96, 2015.

Liu X, Hoang A, Zhou L, Kalra S, Yetil A, Sun M, Ding Z, Zhang X, Bai S, German P, Tamboli P, Rao P, Karam JA, Wood CG, Matin SF, Zurita A, Bex A, Griffioen AW, Gao J, Sharma P, Tannir NM, Sircar K, Jonasch E. Resistance to anti-angiogenic therapy is associated with an immunosuppressive tumor microenvironment in metastatic renal cell carcinoma. Cancer Immunol Res. 3:1017-29, 2015.

Neerincx M, Sie DL, van de Wiel MA, van Grieken NC, Burggraaf JD, Dekker H, Eijk PP, Ylstra B, Verhoef C, Meijer GA, Buffart TE, Verheul HM. MiR expression profiles of paired primary colorectal cancer and metastases by next-generation sequencing. Oncogenesis. 2015 Oct 5;4:e170. doi: 10.1038/oncsis.2015.29.

van Zweeden AA, van der Vliet HJ, Wilmink JW, Meijerink MR, Meijer OW, Bruynzeel AM, van Tienhoven G, Giovannetti E, Kazemier G, Jacobs MA, Verheul HM. Phase I Clinical Trial to Determine the Feasibility and Maximum Tolerated Dose of Panitumumab to Standard Gemcitabine-Based Chemoradiation in Locally Advanced Pancreatic Cancer. Clin Cancer Res. 2015 Oct 15;21(20):4569-75.

Punt S, Thijssen VL, Vrolijk J, de Kroon CD, Gorter A, Jordanova ES. Galectin-1, -3 and -9 expression and clinical significance in squamous cervical cancer. PLoS ONE. In press, 2015 .

Punt S, Houwing-Duistermaat JJ, Schulkens IA, Thijssen VL, Osse EM, de Kroon CD, Griffioen AW, Fleuren GJ, Gorter A, Jordanova ES. Correlations between immune response and vascularization qRT-PCR gene expression clusters in squamous cervical cancer. Mol Cancer 14:71-6, 2015.

Clavel CM, Paunescu, E. Nowak-Sliwinska P, Griffioen AW, Scopelliti R, and Dyson PJ. Modulating the Anticancer Activity of Ruthenium(II)-arene Complexes. J. Med. Chem. 58:3356, 2015.

Paulis YWJ, Huijbers EJM, Van der Schaft DWJ, Soetekouw PMMB, Pauwels P, Tjan-Heijnen VCG, Griffioen AW. CD44 enhances tumor aggressiveness by promoting tumor cell plasticity. Oncotarget, 6:19634-46, 2015.

Clavel CM, Nowak-Sliwinska P, Păunescu E, Griffioen AW, Dyson PJ. Hyperthermia potentiates the therapeutic activity of small-molecule thermoresponsive anticancer drugs in mouse tumor model. Chem. Sci. 6:2795-801, 2015.

Thijssen VL, Heuschen R, Caers J, Griffioen AW. Galectin expression in cancer diagnosis and prognosis: a systematic review. BBA Cancer 1855:235-47, 2015.

Van Beijnum JR, Nowak-Sliwinska P, Huijbers EJM, Thijssen VL, Griffioen AW. The great escape; the hallmarks of resistance to anti-angiogenic therapy. Pharm.Rev. 67:441-61, 2015.

Kleibeuker EA, Ten Hooven MA, Castricum KC, Honeywell R, Griffioen AW, Verheul HM, SlotmanBJ, Thijssen VL. Optimal treatment scheduling of radiation and sunitinib improves the antitumor activity and allows dose reduction. Cancer Med. 4:1003-15, doi: 10.1002/cam4.441, 2015.

Gotink KJ, Broxterman HJ, Honeywell RJ, Dekker H, de Haas RR, Miles KM, Adelaiye R, Griffioen AW, Peters GJ, Pili R, Verheul HM. Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasculature. Oncoscience 1:844-53, 2015.

Păunescu E, Clavel CM, Nowak-Sliwinska P, Griffioen AW, and Dyson PJ, Improved angiostatic activity of Dasatinib by modulation with hydrophobic chains, ASC Medicinal Chemistry Letters 6:313-7, 2015.

Wentink MQ, Huijbers EJM, De Gruijl TD, Verheul HMW, Olsson AK, Griffioen AW. Vaccination approach to angiostatic treatment of cancer. BBA Cancer 1855:155-71, 2015.

Weiss A, Bonvin D, Berndsen RH, Scherrer E, Wong TJ, Dyson PJ, Griffioen AW, Nowak-Sliwinska P. Angiostatic treatment prior to chemo- or photodynamic therapy improves anti-tumor efficacy. Sci.Rep. 11;5:8990, 2015.

Nowak-Sliwinska, P., Weiss A., Van Beijnum JR., Wong TJ., Kilarski WW., Szewczyk G., Verheul HMW, Sarna T, Han den Bergh H, Griffioen AW. Photoactivation of lysosomally sequestered sunitinib after angiostatic treatment causes vascular occlusion and enhances tumor growth inhibition. Cell Death Dis. 12(6)e1641, 2015.

Van Linde ME, Verhoeff JJ, Richel DJ, van Furth WR, Reijneveld JC, Verheul HM, Stalpers LJ. Bevacizumab in Combination With Radiotherapy and Temozolomide for Patients With Newly Diagnosed Glioblastoma Multiforme. Oncologist. 20:107-8, 2015.

Gotink KJ, Rovithi M, de Haas RR, Honeywell RJ, Dekker H, Poel D, Azijli K, Peters GJ, Broxterman HJ, Verheul HM. Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib. Cell. Oncol. 38:119-29, 2015.

Läppchen T, Dings RP, Rossin R, Simon JF, Visser TJ, Bakker M, Walhe P, van Mourik T, Donato K, van Beijnum JR, Griffioen AW, Lub J, Robillard MS, Mayo KH, Grüll H. Novel analogs of antitumor agent calixarene 0118: Synthesis, cytotoxicity, click labeling with 2-[(18)F]fluoroethylazide, and in vivo evaluation. Eur J Med Chem. 89:279-95, 2015.

Kleibeuker EA, Schulkens IA, Castricum KC, Griffioen AW, Thijssen VL. Examination of the role of galectins during in vivo angiogenesis using the chick chorioallantoic membrane assay. Methods Mol Biol. 1207:305-15, 2015.

Schulkens IA, Kleibeuker EA, Castricum KC, Griffioen AW, Thijssen VL. Examination of the role of galectins and galectin inhibitors in endothelial cell biology. Methods Mol Biol. 1207:285-91, 2015.

 

     2014

Neefjes EC, van der Vorst MJ, Boddaert MS, Zuurmond WW, van der Vliet HJ, Beeker A, van den Berg HP, van Groeningen CJ, Vrijaldenhoven S, Verheul HM. Clinical evaluation of the efficacy of methylnaltrexone in resolving constipation induced by different opioid subtypes combined with laboratory analysis of immunomodulatory and antiangiogenic effects of methylnaltrexone. BMC Palliat Care. 13:42, 2014.

Ding X, Liu W, Weiss A, Li Y, Wong I, Griffioen AW, van den Bergh H, Xu H, Nowak-Sliwinska P, Ho CM. Discovery of a low order drug-cell response surface for  applications in personalized medicine. Phys Biol. 11(6)065003, 2014.

Griffioen AW. Angiostatic vaccines, an underestimated approach of cancer therapy, Oncotarget, 5:10961-2, 2014.

Bajou, K., Herkenne, S.,  Thijssen, VL., D'Amico, S., Nguyen, N., Bouché, N., Tabruyn, S., Srahna, M., Carabin, JY., Nivelles, O., Paques, C., Cornelissen, I., Lion, M., Noel, A., Gils, A., Vinckier, S., Declerck, P.J., Griffioen, AW., Dewerchin, M., Martial, J.A., Carmeliet, P., Struman, I. PAI-1 mediates the anti-angiogenic and pro-fibrinolytic effects of 16k-prolactin. Nat. Med. 20:741-7, 2014.

Gotink KJ, Broxterman HJ, Honeywell RJ, Dekker H, de Haas RR, Miles KM, Adelaiye R, Griffioen AW, Peters GJ, Pili R, Verheul HM. Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasculature. Oncoscience 1:844-53, 2014.

Mammatas LH, Verheul HM, Hendrikse NH, Yaqub M, Lammertsma AA, Menke-van der Houven van Oordt CW. Molecular imaging of targeted therapies with positron emission tomography: the visualization of personalized cancer care. Cell Oncol. 38:49-64, 2014.

Griffioen, A.W., Weiss, A., Berndsen, R.H., Abdul, U.K., Te Winkel, M.T., Nowak-Sliwinska, P. The emerging quest for the optimal angiostatic combination therapy. Biochem. Soc. Trans. 42:1608-15, 2014.

Griffioen AW, Thijssen VL. Galectins in tumor angiogenesis. Ann Transl Med. 2:90, 2014, 2014.

Babae, N., Bourajjaj, M., Liu, Y., Van Beijnum, J.R., Cerisoli, F., Scaria, P.V., Verheul, M., Van Berkel, M.P., Pieters, E.H., Van Haastert, R.J., Yousefi, A., Mastrobattista, E., Storm, G., Berezikov, E., Cuppen, E., Woodle, M., Schaapveld, R.Q., Prevost, G.P., Griffioen, A.W., Van Noort, P.I., Schiffelers, R.M. Systemic miRNA-7 delivery inhibits tumor angiogenesis and growth in murine xenograft glioblastoma. Oncotarget 5:6687-700, 2014.

Thijssen, VL, Rabinovich, GA.  Introduction to special issue: Glycans in vascular biology. Glycobiology 24:1235-6:, 2014.

Schulkens IA, Heusschen R, van den Boogaart V, van Suylen R-J, Dingemans A-MC, Griffioen AW, Thijssen VL. Galectin expression profiling identifies galectin-1 and galectin-9∆5 as prognostic factors in stage I/II non-small cell lung cancer. PLoS ONE 9 (9) e107988, 2014.

Weiss, A., Berndsen, R.H., Dubois, M., Müller, C., Schibli, R., Griffioen, A.W., Dyson, P.J., Nowak-Sliwinska, P. In vivo anti-tumor activity of the organometallic ruthenium(II)-arene complex [Ru(ɳ6-p-cymene)Cl2(pta)] (RAPTA-C) in human ovarian and colorectal carcinomas.  Chem. Sci. 5:4742-8, 2014.

Yousefi, A., Bourajjaj, M., Babae, N., Noort, P.I., Schaapveld, R,Q,, Beijnum, J.R., Griffioen, A.W., Storm, G., Schiffelers, R.M., Mastrobattista, E. Anginex lipoplexes for delivery of anti-angiogenic siRNA. Int. J. Pharm. 472:175-84, 2014.

Schulkens, I.A., Castricum, K.C.M., Weijers, E.M., Koolwijk, P., Griffioen, A.W., Thijssen, V.L., Metallothionein expression profiling in human endothelial cells and their role in angiogenesis in vitro. J. Vasc. Res. 51:231-8, 2014.

Rabinovich, GA, Thijssen, VL. Introduction to special issue: Galectins go with the flow. Glycobiology 24:885, 2014.

Thijssen, VL, Griffioen, AW. Galectin-1 and galectin-9 in angiogenesis; A sweet couple. Glycobiology 24:915-20, 2014.

Clavel, CM, Păunescu E, Nowak-Sliwinska P, Griffioen AW, Scopelliti R, Dyson PJ. Discovery of a Highly Tumor-Selective Organometallic Ruthenium(II)-Arene Complex. J Med Chem. 57:3546-58, 2014.

Labots M, Buffart TE, Haan JC, van Grieken NC, Tijssen M, van de Velde CJ, Grabsch HI, Ylstra B, Carvalho B, Fijneman RJ, Verheul HM, Meijer GA. High-level copy number gains of established and potential drug target genes in gastric cancer as a lead for treatment development and selection. Cell. Oncol. 37:41-52, 2014.

Heusschen R., Schulkens I.A., van Beijnum J., Griffioen A.W., Thijssen V.L. Endothelial LGALS9 splice variant expression in endothelial cell biology and angiogenesis. BBA Mol Bas Dis, 1842:284-92, 2014.

Weiss, A., Van Beijnum, J.R., Bonvin, D., Jichlinski, P., Van den Bergh, H., Dyson, P.J., Griffioen, A.W., Nowak-Sliwinska, P. Low-dose angiostatic tyrosine kinase inhibitors improve photodynamic therapy for cancer: lack of vascular normalization, J. Cell. Mol. Med., 18:480-91, 2014.

Sabrkhany, S., Kuijpers, MJE, Verheul, HMW, Oude Egbrink, MGA., Griffioen, AW. Optimal human blood sampling for platelet research. Curr Angiogenesis 2:157-61, 2014.

Barrientos G, Freitag N, Tirado-González I, Unverdorben L, Jeschke U, Thijssen VL, Blois SM. Involvement of galectin-1 in reproduction: past, present and future. Hum Reprod Update, 20:175-93, 2014. 

 

     2013

Nowak-Sliwinska, P., Weiss, A., Sickenberg, M., Griffioen, A.W., Van den Bergh, H. The Role of Photodynamic Therapy in Non-Malignant and Malignant Eye Disorders. J Anal Bioanal Tech. Nov. 2013.doi: 10.4172/2155-9872.S1-007, 2013.

Van Wijk, X.M., Thijssen, V.L., Lawrence, R., Van den Broek, S.A., Dona, Naidu, N., Oosterhof, A., De Westerlo, E.M., Kusters, L.J., Khaled, Y., Jokela, T.A., Nowak-Sliwinska, P., Kremer, H., Stringer, S.E., Griffioen, A.W., Van Wijk, E., Van Delft, F.L., Van Kuppevelt, T.H. Interfering with UDP-GlcNAc metabolism and heparin sulfate expression using a sugar analog reduces angiogenesis. ASC Chem Biol, 8:2331-8, 2013.

Thijssen, VL, Rabinovich, G., Griffioen, A.W. Vascular galectins: regulators of tumor progression and targets for cancer therapy. Cytokine and Growth Factor Reviews 24:547-58, 2013.

Westgeest, H.M., van Erp, N,P,, Honeywell, R.J., Hoekstra, R., Peters, G.J., Verheul, H,M, Successful treatment of renal cell carcinoma with sorafenib after effective but hepatotoxic sunitinib exposure. J Clin Oncol. 31:83-6, 2013.

Bakker,J.L., Meijers-Heijboer, H., Verheul, H. Novel strategies towards the use of anti-angiogenic agents in breast cancer. Eur J Pharmacol. 717:36-9, 2013.

Neerincx, M., Buffart, T.E., Mulder, C.J., Meijer, G.A., Verheul, H.M. The future of colorectal cancer: implications of screening. Gut 62:1387-9, 2013.

Giovannetti, E., Labots, M., Dekker, H., Galvani, E., Lind, J. S., Sciarrillo, R., Honeywell, R., Smit, E. F., Verheul, H. M., and Peters, G. J. Molecular mechanisms and modulation of key pathways underlying the synergistic interaction of sorafenib with erlotinib in non-small-cell-lung cancer (NSCLC) cells. Curr Pharm Des. 19(5):927-39, 2013.

Freitag N, Tirado-González I, Barrientos G, Herse F, Thijssen VL, Weedon-Fekjćr SM, Schulz H, Wallukat G, Klapp BF, Nevers T, Sharma S, Staff AC, Dechend R, Blois SM. Interfering with gal-1-mediated angiogenesis contributes to the pathogenesis of preeclampsia. Proc.Natl. Acad.Sci.USA, 110(28): 11451-6, 2013.

Tugues, S., Honjo, S., König, C., Padhan, N., Kroon, J., Gualandi, L., Li, X., Barkefors, I., Thijssen, V.L., Griffioen, A.W., Claesson-Welsh, L. Tetraspanin CD63 promotes VEGF receptor-2 / β1 integrin complex formation, thereby regulating activation and downstream signaling in endothelial cells in vitro and in vivo.  J. Biol. Chem. 288: 19060-71, 2013.

Heusschen, R., Griffioen, A.W., Thijssen, V.L., Galectin-9 in tumor biology: A jack of multiple trades. BBA Cancer 1836:177-85, 2013.

Nazarov, A., Baquié, M.,  Nowak-Sliwinska, P.,  Zava , O., Van Beijnum, J.R.,  Groessl, M., Chisholm, D.M., Ahmadi, Z.,  McIndoe, S.J., Griffioen, A.W., Van den Bergh, H., Dyson, P.J. Synthesis and characterization of a new class of anti-angiogenic agent based on ruthenium clusters. Scientific Reports 3:1485, 2013.

Lindenberg, J. J., Lougheed, S. M., Van de Ven, R., Zomer, A., Santegoets, S. J., Griffioen, A. W., Hooijberg, E., Van den Eertwegh, A. J., Thijssen, V. L., Scheper, R. J., Oosterhoff, D., and De Gruijl, T. D. Functional characterization reveals STAT3 dependence of a dendritic cell-derived CD14+BDCA3/CD141+ population arising upon IL-10-exposed maturation OncoImmunology, 2:e23837, 2013.

Schulkens IA, Griffioen AW, Thijssen VL. Angiostatic cancer therapy by targeting galectins in the tumor vasculature. In: ACS SymposiumSeries: Galectins and Disease Implications for Targeted Therapeutics. Editors: A. Klysov, ACS Publications, 2013.

Van Beijnum, J.R., Nowak-Sliwinska, P., Van den Boezem, E., Hautvast, P., Buurman, W.A., Griffioen, A.W. Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1. Oncogene 32:363-74, 2013.

Heusschen R, Freitag N, Tirado-González I, Barrientos G, Moschansky P, Muńoz-Fernández R, Leno-Durán E, Klapp BF, Thijssen VL, Blois SM. Profiling Lgals9 Splice Variant Expression at the Fetal-Maternal Interface: Implications in Normal and Pathological Pregnancy. Biol Reprod. 88:22, 2013.

 

     2012

Jarzyna, P.A., Deddens, L.H., Kann, B.H., Ramachandran, S., Calcagno, C., Chen, W., Gianella, A., Dijkhuizen, R.M., Griffioen, A.W., Fayad, Z.A., Mulder, W.J. Tumor Angiogenesis Phenotyping by Nanoparticle-facilitated Magnetic Resonance and Near-infrared Fluorescence Molecular Imaging. Neoplasia 14:964-73, 2012.

Tirado-González, I., Freitag, N., Kobelt, P., Moschansky, P., Klapp, B.F., Thijssen, V.L., Blois, S.M. CXCR4+ Dendritic cells promote angiogenesis during embryo implantation in mice. Angiogenesis 16:417, 2012.

Shapira, A., Livney, Y. D., Broxterman, H. J., and Assaraf, Y. G. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist Updat, 14: 150-163, 2012.

Margadant C, van den Bout I, van Boxtel AL, Thijssen VL, Sonnenberg A. J Epigenetic regulation of galectin-3 expression by β1 integrins promotes cell adhesion and migration. J.Biol.Chem. 287:44684, 2012.

Tirado Gonzalez, I., Barrientos, G., Freitag, N., Otto, T., Thijssen, V.L., Moschansky, P., von Kwiatkowsk, P., Klapp, B.F., Winterhager, E., Bauersachs, S., Blois, S. Uterine NK cells are critical in shaping DC immunogenic functions compatible with pregnancy progression. PlosONE, 7:10, 2012.

Van de Vijver, P., Scheer, L., Van Beijnum, J.R., Griffioen, A.W., Hackeng, T.M. Application of an omonasteine ligation strategy for the total chemical synthesis of the BRD7 bromodomain. Chem.Comm. 14:964-73, 2012.

Griffioen, A.W., Mans, L.A., De Graaf, A.M.A., Nowak-Sliwinska, P., De Hoog, C.L.M.M.,  De Jong, T.A.M., Vyth-Dreese, F.A., Van Beijnum, J.R., Bex, A., Jonasch, E. Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients. Clin. Cancer Res. 18:3961-71, 2012.

Kleibeuker,E.A., Griffioen, A.W., Verheul, H.M., Slotman, B.J., Thijssen, V.L. Combining angiogenesis inhibition and radiotherapy: A double-edged sword.  Drug Resist Updates 15:173-82, 2012.

Michels, M., Van der Ven, A.J.A.M., Djamiatun, K., Fijnheer, R.,De Groot, P.G., Griffioen, A.W., Sebastian, S., Faradz, S.M.H., De Mast, Q. Imbalance of angiopoietin-1 and -2 in severe dengue; relationship with thrombocytopenia, endothelial activation and vascular stability. Am.J.Trop.Med.Hyg. 87:943-946, 2012.

Van der Veldt, A.A., Vroling, L., De Haas, R.R., Koolwijk,  P., Van den Eertwegh, A.J., Haanen, J.B., Van Hinsbergh, V.W., Broxterman, H.J., Boven, E. Sunitinib-induced changes in circulating endothelial cell-related proteins in patients with metastatic renal cell cancer. Int J Cancer. 131:484-93, 2012.

Van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A; CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer. N.Engl.J.Med. 366:2074-84, 2012.

Van der Vliet HJ, Verheul HM. Breast-cancer adjuvant therapy with zoledronic acid. N.Engl.J.Med. 366:188-9, 2012.

Weiss, A., Van Den Bergh, H., Griffioen, A.W., Nowak-Sliwinska, P., Angiogenesis inhibition for the improvement of photodynamic therapy: the revival of a promising idea, BBA Cancer 1826:53-70, 2012.

Bex, A., Etto, T., Vyth-Dreese, F., Blank, C. and Griffioen, A.W. Immunological Heterogeneity of the RCC Microenvironment: Do Targeted Therapies Influence Immune Response? Curr Oncol. Rep. 14(3):230-9,  2012.

Van der Veldt, A. A., Lubberink, M., Bahce, I., Walraven, M., de Boer, M. P., Greuter, H. N., Hendrikse, N. H., Eriksson, J., Windhorst, A. D., Postmus, P. E., Verheul, H. M., Serne, E. H., Lammertsma, A. A., and Smit, E. F. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell, 21: 82-91, 2012.

Adar, Y., Stark, M., Bram, E.E., Nowak-Sliwinska, P., Van den Bergh, H., Szewczk, G., Sarna, T., Skaladanowski, A., Griffioen, A.W., Assaraf, Y.G. Imidazoacridinone-dependent lysosomal photodestruction: a pharmacological Trojan horse approach to eradicate multidrug resistant cancers. Cell Death Dis. In press, 2012.

Paulis, Y.W.J., Dinnes, D., Soetekouw, P.M.M.B., Nelson, P.J., Burdach, S., Loewe, R.P., Tjan-Heijnen, V.C.G., Von Luettichau, I., Griffioen, A.W. Imatinib reduces the vasculogenic potential of plastic tumor cells. Current Angiogenesis 1:64-71, 2012.

Siemerink, M.J., Klaassen, I., Vogels, I.M.C., Griffioen, A.W., Van Noorden, C.J.F., Schlingemann, R.O. CD34 marks angiogenic tip cells in human vascular endothelial cell cultures. Angiogenesis, 15(1):151-63, 2012.

Reuwer, A.Q., Nowak-Sliwinska, P., Mans, L., Van der Loos PhD, C.M., Von der Thüsen, J.H., Twickler, M.Th.B., Spek, A., Goffin, V., Griffioen, A.W., Borensztajn, K.S. Prolactin induces angiogenesis through stimulation of endothelial cell migration. J.Cell.Mol.Med. 16:2035-48,  2012.

Nowak-Sliwinska, P., Weiss A., Van Beijnum, J.R., Wong T.J., Ballini, J.P., Lovisa, B., Van den Bergh, H.,  Griffioen, A.W. Angiostatic kinase inhibitors to sustain photodynamic angio-occlusion. J.Cell.Mol.Med. 16:1553-62, 2012. 

Kluza, E., Jacobs, I., Hectors, S. J., Mayo, K. H., Griffioen, A. W., Strijkers, G. J., and Nicolay, K. Dual-targeting of alpha(v)beta(3) and galectin-1 improves the specificity of paramagnetic/fluorescent liposomes to tumor endothelium in vivo. J Control Release, 158(2):207-14,  2012.

Van der Veldt, A. A., Vroling, L., de Haas, R. R., Koolwijk, P., van den Eertwegh, A. J., Haanen, J. B., van Hinsbergh, V. W., Broxterman, H. J., and Boven, E. Sunitinib-induced changes in circulating endothelial cell-related proteins in patients with metastatic renal cell cancer. Int J Cancer 15:131, 2012.

 

     2011

Gotink, K.J., Broxterman, H.J., Labots, M., De Haas, R.R., Dekker, H., Honeywell, R.J., Beerepoot, L.V., Musters, R.J., Jansen. G.,  Griffioen, A.W., Pili, R., Assaraf, Y.G., Peters, G.J., Verheul, H.M.W. Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin. Cancer Res. 17:7337-46, 2011.

Nilsson, R. J., Balaj, L., Hulleman, E., van Rijn, S., Pegtel, D. M., Walraven, M., Widmark, A., Gerritsen, W. R., Verheul, H. M., Vandertop, W. P., Noske, D. P., Skog, J., and Wurdinger, T. Blood platelets contain tumor-derived RNA biomarkers. Blood, 118: 3680-3683, 2011.

Schneiders, F. L., Scheper, R. J., von Blomberg, B. M., Woltman, A. M., Janssen, H. L., van den Eertwegh, A. J., Verheul, H. M., de Gruijl, T. D., and van der Vliet, H. J. Clinical experience with alpha-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection. Clin Immunol, 140: 130-141, 2011.

Shapira, A., Livney, Y. D., Broxterman, H. J., and Assaraf, Y. G. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist Updat, 14: 150-163, 2011.

Laeremans H, Hackeng TM, van Zandvoort MA, Thijssen VL, Janssen BJ, Ottenheijm HC, Smits JF, Blankesteijn WM. Blocking of Frizzled signaling with a homologous peptide fragment of Wnt3a/Wnt5a reduces infarct expansion and prevents the development of heart failure after myocardial infarction. Circulation, 124:1626-35, 2011.

Gianella, A, Jarzyna PA, Mani V, Ramachandran S, Calcagno C, Tang J, Thijssen VL, Griffioen, AW, Storm G, Fayad ZA, Mulder WJ, A multifunctional nanoemulsion platform for imaging guided therapy evaluated in experimental cancer. ACS Nano, 5:4422-33, 2011.

Nowak-Sliwinska, P, Van Beijnum, JR, Casini, A, Nazarov, A, Wagničres, G, Van den Bergh, H, Dyson, PJ, Griffioen, AW. Organometallic ruthenium(II)-arene compounds with anti-angiogenic activity. J.Med.Chem. 54:3895-3902,  2011.

Langenberg MHG, Witteveen PO, Roodhart J, Lolkema MP,  Verheul HMW,  Mergui-Roelvink M, Brendel E, Krätzschmar J, Loembé B, Nol-Boekel A,  Christensen O, Schellens JHM, Voest EE. Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors. Ann Oncol. 22:2508-15, 2011.

Walraven M, Witteveen PO, Lolkema MP, van Hillegersberg R, Voest EE, Verheul HM. Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review. Angiogenesis 14:135-41, 2011.

Stancic M., van Horssen J., Thijssen V.L., Gabius H-J., Bsibsi M., van der Valk P., Hoekstra D., Baron W. Increased expression of distinct galectins in multiple sclerosis lesions. Neuropath Appl Neuro. 37:654-71, 2011.

Salomonsson E., Thijssen V.L., Griffioen A.W., Nillson U.J., Leffler H. The anti-angiogenic peptide anginex greatly enhances galectin-1 binding affinity for glycoproteins.  J Biol Chem. 286:13801-4, 2011.

Bijnsdorp I.V., Capriotti F., Losekoot N., Kruyt F.A.E., Thijssen V.L., Liekens S., Balzarini J., Griffioen A.W., Fukushima M., Peters G.J.  Thymidine phosphorylase in cancer cells stimulates human endothelial cell migration and invasion by the secretion of angiogenic factors.  Br. J. Cancer. 104:1185-92, 2011.

Pardali, E., Van der Schaft, D.W.J., Wiercinska, E., Gorter, A., Hogendoorn, P.C.W., Griffioen, A.W., Ten Dijke, P. Critical role of endoglin in tumor cell plasticity of Ewing Sarcoma and melanoma. Oncogene, 30:334-45, 2011.

Dings, R.P.M., Vang, K.B., Castermans, K.,  Popescu, F., Zhang, Y., Oude Egbrink, M.G.A., Mescher, M.F., Farrar, M.A., Griffioen, A.W., Mayo, K.H. Enhancement of T-cell mediated anti-tumor response: angiostatic adjuvant to immunotherapy against cancer. Clin. Cancer Res. 17:3134-45, 2011.

Sabrkhany, S.A., Griffioen, A.W., Oude Egbrink, M.G. The role of blood platelets in tumor angiogenesis. BBA - Rev. on Canc. 1815:189- 196, 2011.

Schneiders F.L., van den Berg, H.P., Peters, G.J., Verheul, H.M., van der Vliet, H.J. Severe toxicity of capecitabine following uncomplicated treatment with 5-fluorouracil/leucovorin. Med. Oncol. 28:1136, 2011.

 

     2010  

Nowak-Sliwinska, P., Van Beijnum, J.R., Van Berkel, M., Van den Bergh, H., Griffioen, A.W. Vascular regrowth following photodynamic therapy in the chicken embryo chorioallantoid membrane. Angiogenesis, 13:281-92. 2010.

Biere, S.S., van Weyenberg, S.J., Verheul, H.M., Mulder, C.J., Cuesta, M.A., van der Peet, D.L. Non-metastasizedoesophageal cancer. Ned. Tijdschr. Geneeskd. 154:A820, 2010.

Snoeren, N., Voest, E.E., Bergman, A.M., Dalesio, O., Verheul, H.M., Tollenaar, R.A., van der Sijp, J.R., Schouten, S.B., Rinkes, I.H., van Hillegersberg, R. A randomized two arms phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment. BMC Cancer. 10:545, 2010

Piersma, S.R., Labots, M., Verheul, H.M., Jiménez, C.R. Strategies for kinome profiling in cancer and potential clinical applications: chemical proteomics and array-based methods. Anal Bioanal Chem. 397:3163-71, 2010.

Mulder, W.J.M., Griffioen, A.W. Imaging of angiogenesis. Angiogenesis. 13:71-4, 2010.

Thijssen, V.L., Barkan, B., Shoji, H., Aries, I.M., Mathieu, V., Deltour, L., Hackeng, T.M., Kiss, R., Kloog, Y., Poirier, Y., Griffioen, A.W. Tumor cells secrete galectin-1 to enhance endothelial cell activity. Cancer Res. 70:6216-24, 2010.

Dingemans, A.M.C., Van den Boogaart, V., Vosse, B.A., Van Suylen, R-J., Griffioen, A.W., Thijssen, V.L. Integrin expression profiling identifies integrin alpha5 and beta1 as prognostic factors in early stage non-small cell lung cancer. Mol Cancer. 9:152, 2010.

Mulder, W.J., Strijkers, G.J., Nicolay, K., Griffioen, A.W. Quantum dots for multimodal molecular imaging of angiogenesis. Angiogenesis, 13:131-4, 2010.

Vroling, L., Lind, J.S., de Haas, R.R., Verheul, H.M., van Hinsbergh, V.W., Broxterman, H.J., Smit E.F.  CD133(+) circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients. Br J Cancer. 102:268-75.2010

Van Wijk, X.M., Oosterhof, A.,  Van den Broek, S.A., Griffioen, A.W., Ten Dam, G.B., Rutjes, F.P., Van Delft, F.L., Van Kuppevelt, T.H. A 4-deoxy analogue of N-acetyl-D-glucosamine inhibits heparan sulphate expression and growth factor binding in vitro. Exp Cell Res. 316:2504-12, 2010.

Strijkers, G.J., Kluza, E., Van Tilborg, G.A.F., Van der Schaft, D.W., Griffioen, A.W., Mulder, W.J., Nicolay, K. Paramagnetic and fluorescent liposomes for target-specific imaging and therapy of tumor angiogenesis. Angiogenesis.13(2):161-73, 2010 .

Casal, C., Torres-Callado, AX., Plaza-Calonge Mdel, C., Martino-Echarri, E., Ramón Y Cajal, S., Rojo, F., Griffioen, AW., Rodriguez-Manzaneque, JC. ADAMTS1 contributes tot the acquisition of an endothelial-like phenotype in plastic tumor cells.  Cancer Res. 1;70(11):4676-86, 2010.

Nowak-Sliwinska, P., Wagničres, G., Van den Bergh, H., Griffioen, A.W. Angiostasis-induced vascular normalization can improve photodynamic therapy. Cell Mol Life Sci. 67(9):1559-60, 2010.

Hammers, H.J., Verheul, H.M., Salumbides, B., Sharma, R., Rudek, M., Jaspers, J., Shah, P., Ellis, L., Shen, L., Paesante, S., Dykema, K., Furge, K., Teh, B.T., Netto, G., Pili, R. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Mol Cancer Ther. 2010.  9(6):1525-35.

Giovannetti, E., Funel, N., Peters, G.J., Del Chiaro, M., Erozenci, L.A., Vasile, E., Leon, L.G., Pollina, L.E., Groen, A., Falcone, A., Danesi, R., Campani, D., Verheul, H.M., Boggi, U. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res. 70:4528-38, 2010.

Honeywell, R., Yarzadah, K., Giovannetti, E., Losekoot, N., Smit, E.F., Walraven, M., Lind, J.S., Tibaldi, C., Verheul, H.M., Peters, G.J. Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2010. 878(15-16):1059-68.

Martilla-Ichihara, F., Castermans, K., Auvinen, K., Oude Egbrink, M.G.A., Jalkanen, S., Griffioen, A.W., Salmi, M. Small molecule inhibitors of vascular adhesion protein-1 reduce the accumulation of myeloid cells into tumors and attenuate tumor growth in mice. J. Immunol. 184:3164-73, 2010.

Langenberg, M.H., Witteveen, P.O., Roodhart, J.M., Verheul, H.M., Mergui-Roelvink, M., van der Sar, J., Brendel, E., Laferriere, N., Schellens, J.H., Voest, E.E. Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors. Clin Cancer Res. 16:2187-97, 2010.

Walenkamp, A.M., Bestebroer, J., Boer, I.G., Kruizinga, R., Verheul, H.M., van Strijp, J.A., de Haas, C.J. Staphylococcal SSL5 binding to human leukemia cells inhibits cell adhesion to endothelial cells and platelets. Cell Oncol. 32:1-10, 2010.

Paulis, Y., Soetekouw, P., Verheul, H.M., Tjan-Heijnen, V., Griffioen, A.W.  Signalling pathways in vasculogenic mimicry. BBA Reviews on Cancer, 1806:18-28, 2010.

Gotink K.J., Verheul, H.M. Anti-angiogenic tyrosine kinase inhibitors:what is their mechanism of action? Angiogenesis, 13:1-14, 2010

Heusschen, R., van Gink, M., Griffioen, A.W., Thijssen, V.L. microRNAs in the tumor endothelium: novel controls on the angioregulatory switchboard. BBA Reviews on Cancer, 1805:87-96 2010.

Albrethsen, J., Knol, J. C., Piersma, S., Pham, T. V., de Wit, M., Mongera, S., Carvalho, B., Verheul, H. M., Fijneman, R. J., Meijer, G. A., and Jimenez, C. R. Sub-nuclear proteomics in colorectal cancer:Identification of proteins enriched in the nuclear matrix fraction and regulation in adenoma to carcinoma progression. Mol Cell Proteomics 9:988-1005, 2010.

Banerji, U., Camidge, D. R., Verheul, H. M., Agarwal, R., Sarker, D., Kaye, S. B., Desar, I. M., Timmer-Bonte, J. N., Eckhardt, S. G., Lewis, K. D., Brown, K. H., Cantarini, M. V., Morris, C., George, S. M., Smith, P. D., and van Herpen, C. M. The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer. Clin Cancer Res, 16: 1613-1623.

Vroling, L., Lind, J. S., de Haas, R. R., Verheul, H. M., van Hinsbergh, V. W., Broxterman, H. J., and Smit, E. F. CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients. Br J Cancer, 102: 268-275.

Kluza. E, van der Schaft, DW, Hautvast, PA, Mulder, WJ, Mayo, KH, Griffioen, AW, Strijkers, GJ, Nicolay, K. Synergistic Targeting of alpha(v)beta(3) Integrin and Galectin-1 with Heteromultivalent Paramagnetic Liposomes for Combined MR Imaging and Treatment of Angiogenesis. Nano Letters 10:52-8, 2010.

Chen, W., Jarzyna, P.A., Van Tilborg, G.A.F., Nguyen, V.A., Cormode, D.P., Klink, A., Griffioen, A.W., Randolph, G.J., Fisher, E.A., Mulder, W.J.M., Fayad, Z.A. RGD-peptide funcionalized and reconstituted high density lipoprotein nanoparticles as a versatile and multimodal tumor targeting molecular imaging probe. FASEB J. 24:1689-99. 2010.

van Rooij, E, Fielitz, J, Sutherland, L.B., Thijssen, V.L., Crijns, H.J., Dimaio, M.J., Shelton, J, De Windt, L.J., Hill, J.A., Olson, E.N. Myocyte Enhancer Factor 2 and Class II Histone Deacetylases Control a Gender-Specific Pathway of Cardioprotection Mediated by the Estrogen Receptor. Circ. Res., 8:106:155-65, 2010.

 

     2009  

Overkleeft EN, Goldschmeding R, van Reekum F, Voest EE, Verheul HM. Nephrotic syndrome caused by the angiogenesis inhibitor sorafenib. Ann Oncol. 21:184-5, 2009.

Verheul HM, van Erp K, Homs MY, Yoon GS, van Der Groep P, Rogers C, Hansel DE, Netto GJ, Pili R. The Relationship of Vascular Endothelial Growth Factor and Coagulation Factor (Fibrin and Fibrinogen) Expression in Clear Cell Renal Cell Carcinoma. Urology 75:608-14, 2009.

Adema AD, Bijnsdorp IV, Sandvold ML, Verheul HM, Peters GJ. Innovations and opportunities to improve conventional (deoxy)nucleoside and fluoropyrimidine analogs in cancer. Curr Med Chem. 2009;16(35):4632-43.

van der Vliet HJ, van der Peet DL, Verheul HM. Case 19-2009: Carcinoma of the gastroesophageal junction. N Engl J Med. 361:1315, 2009.

Heideman DA, Thunnissen FB, Doeleman M, Kramer D, Verheul HM, Smit EF, Postmus PE, Meijer CJ, Meijer GA, Snijders PJ. A panel of high resolution melting (HRM) technology-based assays with direct sequencing possibility for effective mutation screening of EGFR and K-ras genes. Cell Oncol. 2009;31(5):329-33.

Broxterman HJ, Gotink KJ, Verheul HM. Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib. Drug Resist Updat. 12:114-26, 2009.

Adema, A. D., Laan, A. C., Myhren, F., Fichtner, I., Verheul, H. M., Sandvold, M. L., and Peters, G. J. Cell cycle effects of fatty acid derivatives of cytarabine, CP-4055, and of gemcitabine, CP-4126, as basis for the interaction with oxaliplatin and docetaxel. Int J Oncol, 36: 285-294, 2009.

Piersma, S. R., Broxterman, H. J., Kapci, M., de Haas, R. R., Hoekman, K., Verheul, H. M., and Jimenez, C. R. Proteomics of the TRAP-induced platelet releasate. J Proteomics, 72: 91-109, 2009.

Verheul, H. M., van Erp, K., Homs, M. Y., Yoon, G. S., van Der Groep, P., Rogers, C., Hansel, D. E., Netto, G. J., and Pili, R. The Relationship of Vascular Endothelial Growth Factor and Coagulation Factor (Fibrin and Fibrinogen) Expression in Clear Cell Renal Cell Carcinoma. Urology, 75:608-14, 2009.

Witjes CD, Verhoef C, Verheul HM, Eskens FA. Systemic treatment in hepatocellular carcinoma; 'A small step for man...'. Neth J Med. 67:86-90, 2009.

Vroling L, van der Veldt AA, de Haas RR, Haanen JB, Schuurhuis GJ, Kuik DJ, van Cruijsen H, Verheul HM, van den Eertwegh AJ, Hoekman K, Boven E, van Hinsbergh VW, Broxterman HJ. Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib. Angiogenesis 12:69-79, 2009.

van der Veldt AA, Boven E, Vroling L, Broxterman HJ, van den Eertwegh AJ, Haanen JG. Sunitinib-induced hemoglobin changes are related to the dosing schedule. J Clin Oncol. 27:1339-40, 2009.

Piersma SR, Broxterman HJ, Kapci M, de Haas RR, Hoekman K, Verheul HM, Jiménez CR. Proteomics of the TRAP-induced platelet releasate. J Proteomics 72:91-109, 2009

Yarzyna, P.A., Skajaa, T., Cormode, D.P., Samber, D., Dickson, S., Griffioen, A.W., Fayad, Z.A., Mulder, W.J. Iron oxide core oil-in-water emulsions as a multifunctional nanoparticle platform for tumor targeting and imaging. Biomaterials, 30:6947-54, 2009.

Tabruyn,, S.P., Memet, S., Ave, P., Verhaeghe, C., Struman, I., Martial, J.A., Griffioen, A.W. NF-kB activation in endothelial cells is critical for the activity of angiostatic agents, Mol. Cancer Ther. 8:2645-54, 2009.

Griffioen, A.W., Vyth-Dreese, F. Angiostasis as a way to improve immunotherapy. Thromb. Haemost., 101:1025-31. 2009.

Van Beijnum, J.R., Petersen, K. Griffioen, A.W. Tumor endothelium is characterized by a matrix remodeling signature. Font. Biosci., 1:216-225, 2009.

Griffioen, AW. Lymphangiogenesis factors target for therapy? Blood, 113:4135-6, 2009.

Mulder, W.J.M., Castermans, K., Van Beijnum, J.R., Oude Egbrink, M.G.A., Chin, P.T.K., Storm, G., Strijkers, G.J., Griffioen, A.W., Nicolay, K. Multimodality molecular imaging of tumor angiogenesis using quantum dots. Angiogenesis, 12:17-24, 2009.

Baldewijns, M.M., Roskams, T., Ballet, V., Van den Eynden G.G., Van Laere, S.J., Van der Auwera, I., Lerut, E., De Bruďne, A.P., Thijssen, V.L., Vermeulen, P.B., Van Poppel, H. Low frequency of lymph node metastasis in clear cell renal cell carcinoma is related to low lymphangiogenic activity, BJU International., 103:1626-31, 2009.

Thijssen, V.L. One less concern. Nature, 457:628-628, 2009.

Eude-Le Parco, I., Gendronneau, G., N'Guyen, T., Delacour, D., Thijssen, V.L., Edelmann, W., Peuchmaur, M., Poirier, F. Genetic assessment of the importance of galectin-3 in cancer initiation, progression and dissemination in mice. Glycobiology, 19:68-75, 2009.

 

       2008  

Van Tilborg, G.A.F., Mulder, W.J.M., Van der Schaft, D.W.J., Reutelingsperger, C.P.M.,  Griffioen, A.W., Strijkers, G.J., Nicolay, K. Improved molecular MR imaging of tumor angiogenesis by avidin-induced clearance of non-bound liposomes. Neoplasia, 10:1459-69, 2008.

Koole, R., Van Schooneveld, M., Hilhorst, J., Mulder, W., Cormode, D., Strijkers, G., Castermans, K., De Mello Donega, C., Vanmaekelbergh, D., Griffioen, A.W., Nicolay, K., Fayad, Z., Meijerink, A. Paramagnetic lipid-coated silica nanoparticles with a fluorescent quantum dot core: a new contrast agent platform for multimodality imaging, Bioconj. Chem., 19:2471-9, 2008.

Castermans, K., Tabruyn, S.P., Zeng, R., Eppolito, C., Leonard, W.J., Shrikant, P.A., Griffioen, A.W. Angiostatic activity of the anti-tumor cytokine interleukin-21. Blood, 112:4940-7, 2008.

Griffioen, A.W. Anti-angiogenesis; making the tumor vulnerable for the immune system. Cancer Immunol. Immunother. 2008;57(10):1553-8.

Van Beijnum, J.R., Rousch, M., Castermans, K., Van der Linden, E., Griffioen, A.W. Isolation of endothelial cells from fresh tissues. Nature Protocols, 3:1085-91, 2008.

Griffioen AW: Angiogenesis, in Cancer Research Encyclopedia, Schwab M (ed): Heidelberg, Springer Verlag, 2008.  

Hillen, F., Kaijzel, E.L., Castermans, K., Oude Egbrink, M.G.A., Löwik, C.W.G.M., Griffioen, A.W. A transgenic Tie2-GFP athymic mouse model; a tool for vascular biology in xenograft tumors, Biochem. Biophys. Res. Comm. 368:364-367, 2008.

Griffioen, A.W. New entry in angiostatic cancer therapy. Blood 111:1755-1756, 2008.

Van Beijnum, J.R., Buurman, W.A., Griffioen, A.W. Convergence and amplification of TLR and RAGE signalling pathways via HMGB1. Angiogenesis 11:91-99, 2008.

Tabruyn, S.P., Griffioen, A.W. NFkB: friend or foe in angiostatic therapy. Angiogenesis 11:101-106, 2008.

Thijssen, V.L.., Hulsmans S, and Griffioen, A. W. The galectin profile of the endothelium; altered expression and localization in activated and tumor endothelial cells. Am J Pathol, 172:545-553, 2008.

Van Beijnum, J. R., Van der Linden, E., and Griffioen, A. W. Angiogenic profiling and comparison of immortalized endothelial cells for functional genomics. Exp Cell Res, 314:264-272, 2008.

Hillen, F. and Griffioen, A. W. Tumor vasculature; sprouting angiogenesis and beyond. Cancer Met. Rev., 26:489-502, 2008.

     2007  

Castermans, K, Griffioen, A. W. Tumor blood vessels, a difficult hurdle for infiltrating leukocytes. Biochim. Biophys. Acta reviews on Cancer, 1767:160-174, 2007.

Van der Schaft, D.W., Pauwels, and Griffioen, A.W. Absence of lymph angiogenesis in breast cancer. Cancer Lett., 256:283-284, 2007.

Thijssen, V. L., Van Beijnum, J. R., Mayo, K.H., and Griffioen, A. W. Identification of novel drug targets for angiostatic cancer therapy; it takes two to tango. Curr. Pharm. Design, 13:3576-3583, 2007.

Thijssen, V. L., Poirier, F., Baum, L. G., and Griffioen, A. W. Galectins in the tumor endothelium; opportunities for combined cancer therapy. Blood, 110:2819-2827, 2007.

Hillen, F., Baeten, C. I., Van de Winkel, A., Creytens, D., Van der Schaft, D. W., Winnepenninckx, V., and Griffioen, A. W. Leukocyte infiltration and tumor cell plasticity are parameters of aggressiveness in primary cutaneuous melanoma. Cancer Immunol. Immunother. 57:97-106, 2007

Mulder, W. J., Griffioen, A. W., Strijkers, G. J., Cormode, D. P., Nicolay, K., and Fayad, Z. A. Magnietic and fluorescent nanoparticles for multimodality imaging. Nanomedicine, 2:307-324, 2007.

Baldewijns, M. M., Thijssen, V. L., Van den Eynden, G. G., Van Laere, S. J., Bluekens, A. M., Roskams, T., Van Poppel, H., De Bruine, A. P., Griffioen, A. W., and Vermeulen, A. H. High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low grade renal cell carcinoma based on histomorphological quantitation and qRT-PCR mRNA expression profile. Brit J Cancer. 96:1888-1895, 2007.

Tabruyn, S. P., Sabatel, C., Verhaeghe, C., Malvaux, L., Castermans, K., Nguyen, N., Cornet, A., Griffioen, A. W., Martial, J. A., and Struman, I. 16K human prolactin overcome endothelial cell anergy and promote leukocyte infiltration in tumors. Mol. Endocrinol. 21:1422-1429, 2007.

Verhaeghe, C., Remouchamps, C., Hennuy, B., Vanderplasschen, A., Chariot, A., Tabruyn, S. P., Oury, C., and Bours, V. Role of IKK and ERK pathways in intrinsic inflammation of cystic fibrosis airways. Biochem. Pharmacol., 73:1982-1994, 2007.

Tabruyn, S. P. and Griffioen, A. W. A new role for NF-kB in angiogenesis inhibition. Cell Death Differ., 14:1393-1397, 2007.

Griffioen, A.W. Therapeutic approaches of angiogenesis inhibition; are we tackling the problem at the right level? Trends Cardiovas. Med. 17:171-176, 2007.

Dings, R. P., Loren, M., Heun, H., McNiel, E., Griffioen, A. W., Mayo, K. H., and Griffin, R. J. Scheduling of radiation with angiogenesis inhibitors Anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res. 13:3395-1402, 2007.

Verhaeghe, C., Tabruyn, S. P., Oury, C., Bours, V., and Griffioen, A. W. An intrinsic pro-angiogenic status of airway epithelial cells in cystic fibrosis. Biochem Biophys Res Commun, 356:745-749, 2007.

Van der Schaft, D.W., Pauwels, P., Hulsmans, S., Zimmermann, M., Van de Poll-Franse, L.V., and Griffioen, A.W. Lymphatic vessel density and expression of VEGF-C and -D are not related to tumor progression and survival in ductal breast cancer. Cancer Lett., 254:128-136, 2007.

Brandwijk, R. J., Griffioen, A. W., and Thijssen, V. L. Targeted gene delivery strategies for angiostatic cancer treatment. Trends Mol Med. 13:200-209, 2007.

Brandwijk, R. J., Mulder, W. J., Nicolay, K., Mayo, K. H., Thijssen, V. L., and Griffioen, A. W. Anginex conjugated liposomes for targeting of angiogenic endothelial cells. Bioconjug Chem. 18:785-790, 2007.

Hellebrekers, D.M.E.I., Melotte, V., Viré, E., Fuks, F., Herman, J.G., Molema, G., Van Criekinge, W., Griffioen, A.W., Van Engeland, M. Identification of epigenetically silenced genes in tumor endothelial cells. Cancer Res. 67:4138-4148, 2007.

Tabruyn, S.P., and Griffioen, A. W. Molecular pathways of angiogenesis inhibition. Biochem Biophys Res Commun, 355:1-5, 2007.

Mulder, W.J.M., Van der Schaft, D.W.J., Hautvast, P.A.I., Strijkers, G.J., Storm, G., Mayo, K.H., Griffioen, A. W., and Nicolay, K. Early in vivo assessment of angiostatic therapy efficacy by molecular MRI. FASEB J., 21:378-383, 2007.

Hellebrekers, D.M.E.I., Griffioen, A.W., Van Engeland, M. Dual targeting of epigenetic therapy in cancer. Biochim Biophys Acta 1775:76-91, 2007.

Hillen, F., Melotte, V., Van Beijnum, J.R., Griffioen, A.W., Endothelial cell biology. In: Angiogenesis assays: a critical appraisal of current techniques. Eds: Carolyn Staton, Claire Lewis, Roy Bicknell. John Wiley & Sons Ltd, 2007.

     2006  

Thijssen, V. L., Postel, R., Brandwijk, R. J., Dings, R. P., Nesmelova, I., Satijn, S. A., Verhofstad, N., Nakabeppu, Y., Baum, L. G., Bakkers, J., Mayo, K. H., Poirier, F., and Griffioen, A. W. Galectin-1 is essential in angiogenesis and is a target for anti-angiogenesis therapy. Proc.Natl.Acad.Sci.USA, 103:15975-15980, 2006

Derksen, P.W., Liu, X., Saradin, F., Evers, B., Van Beijnum, J.R., Griffioen, A.W., Van der Gulden, H., Zevenhoven, J., Peterse, H., Cardiff, R., Vink, J., Krimpenfort, P., Berns, A., and Jonkers, J. Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell, 10:437-449, 2006

Hellebrekers, D. M., Castermans, K., Vire, E., Dings, R. P., Hoebers, N. T., Mayo, K. H., Oude Egbrink, M. G., Molema, G., Fuks, F., van Engeland, M., and Griffioen, A. W. Epigenetic regulation of tumor endothelial cell anergy; silencing of ICAM-1 by histone modifications. Cancer Res., 66:10770-10777, 2006.

Griffioen, A. W. Angiogenesis: fundamental and clinical perspectives. Angiogenesis, 9:155-170, 2006.

Brandwijk, R. J., Dings, R. P. M., Van der Linden, E., Mayo, K. H., Thijssen, V. L., and Griffioen, A. W. Anti-angiogenesis and anti-tumor activity of recombinant anginex. Biochem Biophys Res Commun, 349:1073-1078, 2006.

Dirkx, A.E.M., Oude Egbrink, M.G., Wagstaff, J., Griffioen, A.W. Monocyte/macrophage infiltration in tumors; modulators of angiogenesis. J.Leuk.Biol. 80:1183-1196, 2006.

Baeten, C. I., Castermans, K., Lammering, G., Hillen, F., Wouters, B. G., Hillen, H. F., Griffioen, A. W., and Baeten, C. M. Effects of radiotherapy and chemotherapy on angiogenesis and leukocyte infiltration in rectal  cancer. Int.J.Radiation Oncology Biol.Phys., 66: 1219-1227, 2006.

Dings, R.P., Chen, X., Nesmelova, I., Haseman, J., Hellebrekers, D.M.E.I., Maxwell, J., Van Eijk, L.I., Hoye, T.R., Griffioen, A.W., Mayo, K.H., Design of non-peptidic helix/sheet topomimetics: applications to inhibition of angiogenesis and tumor growth in mice. J Natl Cancer Inst, 98:932-936, 2006.

Flati, V., Pastore, L.I., Griffioen, A.W., Satijn, S., Toniato, E., D'Alimonte, I., Laglia, E., Marchetti, P., Gulino, A., Martinotti, S. Endothelial cell anergy is mediated by bFGF through the sustained activation of p38-MAPK and NF-kB inhibition. Int.J.Immunopathol.Pharmacol. 19:761-773, 2006.

Hillen, F., Van de Winkel, A., Baeten, C.I.M., Creytens, D., Vermeulen, T., Griffioen, A.W. Proliferating endothelial cells, but not microvessel density, is a prognostic parameter in human cutaneous melanoma. Melanoma Res. 16:453-547, 2006.

Van Beijnum, J.R., Dings, R.P.M., Zwaans, B., Van der Linden, E., Ramaekers, F.C.S., Mayo, K.H. and Griffioen, A. W. Gene expression of tumor angiogenesis dissected; specific targeting of colon cancer angiogenic vasculature. Blood, 108:2339-2348, 2006.

Baeten,C.I.M., Castermans, K., Hillen, H.F.P., Griffioen, A.W. Proleferatingendothelial cells and leukocyte infiltration are related prognostic markers incolorectal cancer. Clin. Gastroenterol. Hepatol. 4:1351-7, 2006.

Punyadeera, C., Thijssen, V. L. J. L., Tchaikovski, S., Gashaw, I., Kamps, R., Dunselman, G. A. J., De Goeij, A. F. P. M., Winterhager, E., Griffioen, A. W., Groothuis, P. G. Biphasic angiogenesis response in proliferative phase human endometrium. Mol.Hum.Reprod., 12:367-375, 2006.

Ahmed, B., Landuyt, W., Griffioen, A. W., van Oosterom, A., Van den Bogaert, W., Lambin, P. In vivo antitumor effect of combretastatin A-4 phosphate added to fractionated irradiation. Anticancer Res. 26:307-310, 2006.

Hellebrekers, D. M. E. I., Jair, K. W., Eguchi, S., Hoebers, N. T. H., Vire, E., Fraga, M. F., Fuks, F., Esteller, M., Baylin, S. B., van Engeland, M., Griffioen, A. W. Epigenetic regulation of angiogenesis; DNA methyltransferase inhibitors have angiostatic activity. Mol.Cancer Ther. 5:467-475, 2006.

Langereis, S., De Lussanet, Q. R., Van Genderen, M. H. P., Meijer, E. W., Beets-Tan, R. G. H., Griffioen, A. W., Van Engelshoven, J. M. A., Backes, W. H. Evaluation of Gd(III)DTPA-terminated poly(propylene imine) dendrimers as contrast agents for MR imaging. NMR Biomed. 19:133-41, 2006.

Dirkx, A. E. M., oude-Egbrink, M. G., Castermans, K., Thijssen, V. L. J. L., Van der Schaft, D. W. J., Dings, R.P.M., Kwee, L., Mayo, K. H., Wagstaff, J., Bouma-Ter Steege, J. C. A., Griffioen, A. W. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J. 20:621-30, 2006.

Van Beijnum, J. R., Eijgelaar, W. J., Griffioen, A. W. Target identification and validation in angiogenesis research; a shift in focus. From gene to function or from function to gene? Trends Mol. Med., 12(1):44-52, 2006.

Van Beijnum, J.R., Griffioen, A.W. [Genexpressieanalyse van tumor angiogenese: van target naar therapie. Kanker 30: 6-9, 2006.

Griffioen, A.W., Thijssen, V.L. Angiogenesis: fundamental and clinical perspectives. Angiogenese Journaal 1:11-13, 2006.

Mulder, W. J. M., Strijkers, G. J., Van Tilborg, G. A. F., Griffioen, A. W., Nicolay, K. Lipid based nanoparticles for contrast enhanced MRI and molecular imaging. NMR Biomed. 19(1):142-64, 2006.

Mulder, W. J. M., Koole, R., Brandwijk, R. J., Storm, G., Chin, P., Strijkers, G. J., Celso de Mello Donega, Nicolay, K., Griffioen, A. W. Paramagnetic quantum dots as a bimodal molecular imaging probe for angiogenesis. Nano Letters. 6:1-6, 2006.

 

        2005  

Van der Schaft, D. W. J., Hillen, F., Pauwels, P., Kirschmann, D. A., Castermans, K., oude Egbrink, M. G. A., Tran, M. G. B., Sciot, R., Hauben, E., Hogendoorn, P. C. W., Delattre, O., Maxwell, P. H., Hendrix, M. J. C., Griffioen, A. W. Tumor cell plasticity in Ewing sarcoma; an alternative circulatory system stimulated by hypoxia. Cancer Res., 65:11520-8, 2005.

Mulder, W. J. M., Strijkers, G. J., Habets, J., Bleeker, E. J. W., Van der Schaft, D. W. J., Storm, G., Koning, G. A., Griffioen, A. W., and Nicolay, K. MR Molecular Imaging and Fluorescence Microscopy for identification of Activated Tumor Endothelium Using a Bimodal Lipidic Nanoparticle. FASEB J., 19:2008-10, 2005..

Van Beijnum, J. R. and Griffioen, A. W. In silico analysis of angiogenesis associated gene expression identifies angiogenic stage related profiles. BBA Cancer, 1755:121-34, 2005.

Brandwijk, R., Nesmelova, I., Dings, R. P. M., Mayo, K. H., Thijssen, V. L. J. L., and Griffioen, A. W. Cloning of an artificial gene encoding anginex: from rational in silico designed angiostatic peptide to functional recombinant protein. Biochem.Biophys.Res.Commun., 333:1261-8, 2005.

De Lussanet, Q. R., Backes, W. H., Griffioen, A. W., Padhani, A. R., Baeten, C. I. M., Van Baardwijk, A., Lambin, P., Beets, G. L., Van Engelshoven, J. M. A., and Beets-Tan, R. G. H. Dynamic contrast enhanced magnetic resonance imaging of radiation therapy induced microcirculation changes in rectal cancer. Int.J.Rad.Oncol.Biol., 63:1309-15, 2005.

Nap, A. W., Dunselman, G. A. J., Griffioen, A. W., Mayo, K. H., Evers, J. L. H., and Groothuis, P. G. Angiostatic agents prevent the development of endometriosis-like lesions in the chicken chorioallantoic membrane. Fertil.Steril., 83:793-5, 2005.

Dings, R. P. M., Williams, B. W., Song, C. W., Griffioen, A. W., Mayo, K. H., and Griffin, R. Antiangiogenic peptide anginex synergizes with radiation therapy to cause tumor growth inhibition and regression via endothelial cell radiosensitization. Int.J.Cancer, 115:312-9, 2005.

De Lussanet, Q. R., Langereis, S., Beets-Tan, R. G. H., Van Genderen, M., Griffioen, A. W., Van Engelshoven, J. M. A., and Backes, W. H. Relationship between dynamic contrast-enhanced MR imaging kinetic parameters and molecular weight of dendritic contrast agents in tumor angiogenesis. Radiology, 235:65-72, 2005.

Nesmelova, I. V., Sham, Y., Dudek, A. Z., Van Eijk, L. I., Wu, G., Slungaard, A., Mortari, F., Griffioen, A. W., and Mayo, K. H. PF4 and IL8 CXC-Chemokine heterodimer formation modulates function at the quarternary level. J.Biol.Chem., 280(6):4948-58, 2005.

 

        2004  

Bouma-Ter Steege, J. C. A., Baeten, C. I. M., Thijssen, V. L. J. L., Satijn, S. A., Verhoeven, I. C. L., Hillen, H. F. P., Wagstaff, J., and Griffioen, A. W. Angiogenic profile of breast cancinoma determines leukocyte infiltrate. Clin.Cancer Res., 10:7171-8, 2004.

Thijssen, V. L. J. L., Brandwijk, R., Dings, R. P. M., and Griffioen, A. W. Angiogenesis gene expression profiling in xenograft models to study cellular interactions. Exp.Cell Res., 299: 286-293, 2004.

Van der Schaft, D. W. J., Seftor, E. A., Hess, A. R., Gruman, L. M., Yokoyama, Y., Griffioen, A. W., and Hendrix, M. J. C. Differential effects of angiogenesis inhibitors on vascular network formation by endothelial cells versus aggressive melanoma tumor cells. J.Natl.Cancer Inst., 96: 1473-1477, 2004.

Derks S, Lentjes MH, Hellebrekers DM, de Bruine AP, Herman JG, van Engeland M Methylation-specific PCR unraveled. Cell Oncol. 26:291-9, 2004.

Griffioen, A. W. Development of designed angiogenesis inhibitors and peptide-mimetics. Angiogenesis, 6: 356-358, 2004.

Mulder, W. J. M., Strijkers, G. J., Griffioen, A. W., Van Bloois, L., Molema, G., Storm, G., Koning, G. A., and Nicolay, K. A liposomal system for contrast-enhanced MR imaging of molecular targets. Bioconjugate Chem., 15: 799-806, 2004.

Matzen, K., Dirkx, A. E. M., oude Egbrink, M. G. A., Speth, C., Goette, M., Quadt, I., Ascherl, G., Griffioen, A. W., and Stuerzl, M. HIV-1 Tat increases adhesion of monocytes and T-cells to the endothelium in vitro and in vivo: Implications for AIDS associated vasculopathy. Virus Res., 104, 145-155, 2004.

De Lussanet, Q. R., Beets-Tan, R. G. H., Backes, W. H., Van der Schaft, D. W. J., Van Engelshoven, J. M. A., Mayo, K. H., and Griffioen, A. W. Dynamic contrast-enhanced magnetic resonance imaging at 1.5 T with Gd-DTPA to assess angiostatic effects of anginex in mice. Eur.J.Cancer, 40: 1262-1268, 2004.

Nap, A. W., Griffioen, A. W., Dunselman, G. A. J., Bouma-Ter Steege, J. C. A., Thijssen, V. L. J. L., Evers, J. L. H., and Groothuis, P. G. Anti-angiogenesis therapy for endometriosis. J.Clin.Endocr.Metab., 83: 1089-1095, 2004.

Van de Wouw, A. J., Jansen, R. L. H., Griffioen, A. W., and Hillen, H. F. P. Clinical and immunohistochemical analysis of patients with unknown primary tumor. Anticancer Res., 24: 297-301, 2004.

 

        2003  

Van Beijnum, J. and Griffioen, A. W. Transcriptional profiling of angiogenically activated endothelial cells; gene expression reflects the angiogenic stage. Appl.Genomics Proteomics, 2: 207-223, 2003.

Dings, R. P. M., Nesmelova, I., Griffioen, A. W., and Mayo, K. H. Discovery and development of antiangiogenic peptides: a structural link. Angiogenesis, 6: 83-91, 2003.

Van Beijnum, J. R., Fan, T. P., and Griffioen, A. W. Euroconference Angiogenesis II. Angiogenesis, 6: 159-164, 2003.

Mayo, K.H., Dings, R.P.M., Flader, C., Nesmelova, I., Hargittai, B., Van der Schaft, D.W.J., Van Eijk, L., Walek, D., Haseman, J., Hoye, T.R., Griffioen, A.W. Design of a partial-peptide mimetic of anginex with antiangiogenic and anticancer activity. J.Biol.Chem., 278:45746-45752, 2003.

Mayo, K. H. and Griffioen, A. W. Designing beta-pep peptides: a rational approach to discovery of novel pharmaceutical agents and small molecules. Drugs of the Future, 28:337-346, 2003.

Dings, R. P. M., Arroyo, M., Van Eijk, L. I., Griffioen, A. W., and Mayo, K. H. Beta-sheet is the bioactive conformation of the anti-angiogenic peptide anginex. Biochem. J. 373:281-188, 2003.

Dirkx, A., oude Egbrink, M. G. A., Kuipers, M., Van de Niet, S. T., Heijnen, V. V. T., Wagstaff, J., and Griffioen, A. W. Tumor angiogenesis modulates leukocyte-vessel wall interactions in relation to tumor size. Cancer Res., 63:2322-2329, 2003.

Dings RPM, Van der Schaft DWJ, Hargittai B, Haseman J, Griffioen AW, and Mayo KH. Anti-tumor activity of the novel angiogenesis inhibitor anginex. Cancer Letters, 35:1-12, 2003

Ahmed B, Van Eijk L, Bouma-Ter Steege JCA, Van der Schaft DWJ, Van Esch AM, Lambin P, Landuijt W, and Griffioen AW, A defined role of angiogenesis inhibition in the overall vascular targeting activity of combretastatin A-4 phosphate. Int.J.Cancer, 104:87-94, 2003.

Dings RPM, Hargittai B, Haseman J, Griffioen AW, and Mayo KH, The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin. Cancer Res., 63:382-5, 2003.

De Lussanet, Q. R., Backes, W. H., Griffioen, A. W., Van Engelshoven, J. M. A., and Beets-Tan, R. G. H. Gd-DTPA versus USPIO for dynamic contrast-enhanced MRI of tumor angiogenesis in human colon carcinoma in mice. Radiology, 229:429-438: 2003.

 

        2002  

Jayson GC, Zweit J, Jackson A, Mulatero C, Julyan P, Ranson M, Broughton L, Wagstaff J, Hakannson L, Groenewegen G, Bailey J, Smith N, Hastings D, Lawrance J, Haroon H, Ward T, McGown AT, Tang T, Levitt D, Marreaud S, Lehmann F.F, Herold M, Zwierzina H. Molecular Imaging and Biological evaluation of HuMV833 anti-VEGF antibody: Implications for trial design of anti-angiogenic antibodies. J.Natl.Cancer Inst. 2002, 94:1484.

Van der Schaft DWJ, Dings RPM, De Lussanet QR, Van Eijk LI, Nap AW, Beets-Tan RGH, Bouma-Ter Steege JCA, Wagstaff J, Mayo KH, Griffioen AW. The designer anti-angiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal models. FASEB J., 16:1991-3, 2002.

Baeten CIM, Wagstaff J, Verhoeven ICL, Hillen HFP and Griffioen AW. Flow cytometric quantification of tumor endothelial cells; an objective alternative for microvessel density assessment. Br.J.Cancer, 87:344, 2002.

Bouma-Ter Steege JCA, Mayo KH, Griffioen AW. Angiostatic proteins and peptides. Crit.Rev.Euk.Gene Expr. 11: 41-55, 2002

Van der Schaft DWJ, Wagstaff J, Mayo KH, Griffioen AW. The antiangiogenic properties of bactericidal/permeability-increasing protein (BPI).. Ann.Med. 34:19-27, 2002.

 

        2001  

Griffioen AW: Angiogenesis, in Schwab M (ed): Cancer Research Encyclopedia, Heidelberg, Springer Verlag, 2001.  

Van der Schaft DWJ, Ramakrishnan S, Molema G, Griffioen AW: Tumor vascular targeting, in G.Molema (ed): Organ specific drug targeting. Springer 2001, pages 233-254.

Mutuberria R, Arends JW, Griffioen AW, Hoogenboom HR: Phage display technology for target discovery in drug delivery research, in G.Molema (ed): Organ specific drug targeting. Springer 2001, pages 255-271.  

Griffioen AW, Van der Schaft DWJ, Barendsz-Janson AF, Cox A, Struijker Boudier HAJ, Hillen HFP, Mayo KH: Anginex, a designed peptide that inhibits angiogenesis. Biochem.J. 354:233, 2001.

Groenewegen, G., Griffioen, A.W. Phenotype analysis of endothelium from the tumor vasculature. In: Tumor angiogenesis and microcirculation. pp 181-186. New York, Marcel Decker Inc., 2001.   

Mayo KH, Van der Schaft DWJ, Griffioen AW: Designed beta-sheet peptides that inhibit proliferation and induce apoptosis in endothelial cells. Angiogenesis, 4:15, 2001  

 

        2000

Tromp SC, oude Egbrink MGA, Dings RPM, Van Velzen S, Slaaf DW, Hillen HFP, Tangelder GJ, Reneman RS, Griffioen AW: Tumor angiogenesis factors reduce leukocyte adhesion in vivo. Int.Immunol. 12: 671-676, 2000

Griffioen AW, Molema G: Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases and chronic inflammation. Pharmacol.Rev. 52: 237-268, 2000

Yokoyama Y, Dhanabal M, Griffioen AW, Sukhatme VP, Ramakrishnan S: Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth. Cancer Res. 60: 2190-2196, 2000

Griffioen AW: AG3340/prinomastat; an evaluation. Curr.Opin.Oncol.Endo.Metabol.Invest.Drugs 1: 573-582, 2000

Van der Schaft DWJ, Toebes EAH, Haseman J, Mayo KH, Griffioen AW: Bactericidal permeability increasing protein (BPI) inhibits angiogenesis via induction of apoptosis in vascular endothelial cells. Blood 96: 176-181, 2000.

Wild R, Ramakrishnan S, Sedgewick J, Griffioen AW: Computer assisted digital image analysis for the quantitative assessment of tumor angiogenesis: inhibition by VEGF-toxin conjugate. Microvasc.Res. 59: 368-376, 2000.

Hillen, HFP: Unknown primary tumours. Postgrad. Med. 76: 690-693, 2000.

 

        1999

Griffioen AW, Van der Schaft DWJ, Cox A, Visentin G, Struijker Boudier HAJ, Hillen HFP, Wagstaff J, Mayo KH: Anginex/ßpep-25, a designed peptide cytokine that inhibits angiogenesis. Proc.Am.Ass Cancer Res. 40: 433, 1999

Griffioen AW, Relou IAM, Gallardo Torres HI, Damen CA, Martinotti S, De Graaf JC, Zwaginga JJ, Groenewegen G: Tumor angiogenesis impairs leukocyte adhesion and rolling under flow conditions. Angiogenesis 2: 45-50, 1999

Pappas NP, Hillen HFP, Wagstaff J, Griffioen AW: Tumor angiogenesis regulates the tumor immune response. Ned.Tijdschr.Geneesk. 143: 1555-1559, 1999

Griffioen AW, Damen CA, Mayo K, Barendsz-Janson AF, Martinotti S, Blijham GH, Groenewegen G: Angiogenesis inhibitors overcome tumor induced endothelial cell anergy. Int.J.Cancer 80: 315-319, 1999.

Saleh AW, Hillen HF, Duits AJ: Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia patients during hydroxyurea therapy. Acta Haematol. 102: 31-7, 1999

Luykx-de-Bakker SA, de-Gruijl TD, Scheper RJ, Wagstaff J, Pinedo HM: Dendritic cells: A novel therapeutic modality. Ann.Oncol. 10: 21-27, 1999.


         1998

Griffioen AW, Barendsz-Janson AF, Mayo KH, Hillen HFP: Angiogenesis, a target for tumor therapy. J.Lab.Clin.Med. 132: 363-368, 1998

Barendsz-Janson AF, Griffioen AW, Muller AD, Van Dam-Mieras MCE, Hillen HFP: In vitro tumor angiogenesis assays: plasminogen lysine binding site 1 (LBS-1) inhibits in vitro tumor induced angiogenesis. J.Vasc.Res. 35: 109-114, 1998

Griffioen AW, Fan TP: Merger of Angiogenesis and Angiogenesis Research. Angiogenesis 2: 201-202, 1998

Relou IAM, Damen CA, Van der Schaft DWJ, Groenewegen G, Griffioen AW: The effect of culture conditions on endothelial cell phenotype and responsiveness. Tissue Cell 30: 525-530, 1998

Griffioen AW, Tromp SC, Hillen HFP: Angiogenesis modulates the tumor immune response. Int.J.Exp.Pathol. 79: 363-368, 1998

Lichtenbeld H, Barendsz-Janson AF, Van Essen H, Struijker Boudier HAJ, Griffioen AW, Hillen HFP: Angiogenic potential of malignant and non-malignant human breast tissues in an in vivo angiogenesis model. Int.J.Cancer 77: 455-459, 1998

Molema G, Griffioen AW: Rocking the foundations of solid tumor growth by attacking the tumor's blood supply. Immunol.Today 19: 392-394, 1998

Hillen HF, Hak LE, Joosten-Achjanie SR, Arends JW: Microvessel density in unknown primary tumors. Int.J.Cancer 74: 81-5, 1998.